<DOC>
	<DOC>NCT02763969</DOC>
	<brief_summary>The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.</brief_summary>
	<brief_title>Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Healthy Male and Female participants 18 to 50 years of age (Parts AD) 18 to 70 years of age (Part E) Diagnosed with plaque psoriasis (Part E) Participants that had recent infections Participants with Low Blood Pressure Participants with any heart related problems Participants with cancer Participants with any other major medical illness Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>